Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284082 · ClinicalTrials.gov registry record
The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women
A clinical trial, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 90
- Enrollment target
NCT07284082: Recruiting study, sponsored by University of California, San Francisco.
NCT07284082 is a clinical trial that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284082 is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
Study Summary
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.
Primary Outcome
sCD14 (monocyte activation), sCD163 (M2 macrophage activation), CRP (inflammation), IL-6 (inflammation), IP-10 (interferon-inducible protein), TNFα (inflammation), MCP-1 (inflammation), sTNFRI \& RII (inflammation). There are no units as they will be normalized based upon their interquartile range.
Interventions
- DIAGNOSTIC_TEST Whole body MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2030-03-01 |
What NCT07284082 shows while recruiting
NCT07284082 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Whole body MRI is the first listed.
NCT07284082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07284082 about?
NCT07284082 is a clinical study titled "The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women". Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menop...
What is the current status of trial NCT07284082?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2026-04-17. Estimated completion is 2030-03-01.
What interventions are being tested in trial NCT07284082?
The interventions under investigation include: Whole body MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07284082?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI